Cure in the Code

Peter Huber is a senior fellow at the Manhattan Institute, where he specializes in issues of drug development, energy, technology, and the law, and is also a partner at the law firm of Kellogg, Huber, Hansen, Todd, Evans & Figel. He lives in Hanover, New Hampshire.

"[An] urgent, compelling account of how 21st-century medicine is being hampered by a regulatory regime built for the science of the 20th century." --Wall Street Journal "[An] exciting and authoritative review of accelerating advances in personalized medicine." --Barron's "Spotlighting an area where federal laws and regulations lag far behind technological innovation, the author, a Manhattan Institute senior fellow, maintains that medicine's rapidly developing capacity to decode individual human genomes and tailor patients' treatments accordingly -- as with breast cancer -- is being hindered by...'outdated drug-approval protocols developed decades ago during medicine's long battle with the infectious epidemics of the past.'" --Pittsburgh Tribune-Review "A must read for physicians, patients, biotech investors, and healthcare politicians, The Cure in the Code is the most important policy book of the decade, and it could only have been written by Peter Huber, a polymathic master of both the deadly menace and huge promise of bioscience, and scathing critic of the blindness of healthcare bureaucracy." --George Gilder, author of Knowledge and Power: The Information Theory of Capitalism "A thoughtful and compelling account of how the federal government's current regulatory science is not only outdated, but risks hampering scientific efforts to combat diseases at the molecular level. Marshaling insights from medicine, law, and economics, Huber makes an urgent case for how to improve the drug and therapy regulatory system to better equip physicians with innovative treatments that meet critical patient needs." --Tom Coburn, M.D., United States Senator from Oklahoma "[Huber is] one of the few men walking the Earth who could write a book about FDA reform that is not only profitable but pleasurable to read. The book is exciting, in that it suggests possibilities for significant improvements in our ability to treat terrifying diseases in the near future; but it is also depressing, because its sophisticated analysis -- in flying so far above regulation-deregulation and government-market binaries that dominate so many of our policy debates -- cannot help but draw one's attention to the intellectual poverty of Washington's practically pre-Copernican approach to important policy decisions... The book is sprinkled liberally with sentences that are thought-provoking gems, each worthy of an essay of its own... [A] very rich book." --National Review "Our ability to read the genetic code heralds a transformation of modern medicine. Yet many potential medical miracles remain throttled...[Huber's] ardor for invigorating pharmaceutical progress is apparent on every page." --Booklist "Intriguing." --Kirkus Reviews "A provocative, optimistic look at modern medicine... Huber's challenge is sure to spark controversy as the U.S. adapts to the Affordable Care Act." --Publishers Weekly